2,4,5-Trimethoxyldalbergiquinol promotes osteoblastic differentiationand mineralization via the BMP and Wnt/beta-catenin pathway

Collection with item attached
2015
Item details URL
http://open-repository.kisti.re.kr/cube/handle/open_repository/473411.do
DOI
10.1038/cddis.2015.185
Title
2,4,5-Trimethoxyldalbergiquinol promotes osteoblastic differentiationand mineralization via the BMP and Wnt/beta-catenin pathway
Description
This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government (MEST; No, 2012R1A5A2051384)
abstract
Dalbergia odorifera has been traditionally used as a medicine to treat many diseases. However, the role of 2,4,5-trimethoxyldalbergiquinol (TMDQ) isolated and extracted from D. odorifera in osteoblast function and the underlying molecular mechanisms remain poorly understood. The aim of this study was to investigate the effects and possible underlying mechanisms of TMDQ on osteoblastic differentiation of primary cultures of mouse osteoblasts as an in vitro assay system. TMDQ stimulated osteoblastic differentiation, as assessed by the alkaline phosphatase (ALP) activity, ALP staining, mineralized nodule formation, and the levels of mRNAs encoding the bone differentiation markers, including ALP, bone sialoprotein (BSP), osteopontin, and osteocalcin. TMDQ upregulated the expression of Bmp2 and Bmp4 genes, and increased the protein level of phospho-Smad1/5/8. Furthermore, TMDQ treatment showed the increased mRNA expression of Wnt ligands, phosphorylation of GSK3, and the expression of beta-catenin protein. The TMDQ-induced osteogenic effects were abolished by Wnt inhibitor, Dickkopf-1 (DKK1), and bone morphogenetic protein (BMP) antagonist, noggin. TMDQ-induced runt-related transcription factor 2 (Runx2) expression was attenuatted by noggin and DKK1. These data suggest that TMDQ acts through the activation of BMP, Wnt/beta-catenin, and Runx2 signaling to promote osteoblast differentiation, and we demonstrate that TMDQ could be a potential agent for the treatment of bone loss-associated diseases such as osteoporosis.
provenance
Made available in Cube on 2018-09-28T10:18:47Z (GMT). No. of bitstreams: 0
language
English
author
Yun, H-M
Park, K-R
Quang, T. H.
Oh, H.
Hong, J. T.
Kim, Y-C
Kim, E-C
accessioned
2018-09-28T10:18:47Z
available
2018-09-28T10:18:47Z
issued
2015
citation
CELL DEATH & DISEASE(6)
issn
2041-4889
uri
http://open-repository.kisti.re.kr/cube/handle/open_repository/473411.do
Funder
미래창조과학부
Funding Program
선도연구센터지원
Project ID
1711028371
Jurisdiction
Rep.of Korea
Project Name
Center for Innovative Cancer Therapeutics
rights
openAccess
type
article


Files in This Item

There are no attached files.